Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.9K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

805
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

952
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
952
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

753
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

481
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
481
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

460
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
460

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Bayesian-Based Integrative Bioinformatics Analysis Nominates Oncogenic Drivers in Neuroblastoma.

Clinical and translational science·2026
Same author

Targeting the METTL1/m7G axis as a therapeutic strategy in myeloid leukemia.

Blood·2026
Same author

A human cardiomyocyte screen identifies optimized lipid nanoparticles for in vivo cardiac gene editing.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Nrf1 coordinates proteasome activity and autophagy to maintain cardiac proteostasis.

Communications biology·2026
Same author

SpaFun: discovering domain-specific spatial expression patterns and new disease-relevant genes using functional principal component analysis.

Briefings in bioinformatics·2026
Same author

Claudins interact with LILRB immune inhibitory receptors to promote myeloid immunosuppression in cancer.

Science immunology·2026
Same journal

A Bundle to Frame Guidelines and American Heart Association Statements.

Circulation·2026
Same journal

<i>Circulation</i> Editors and Editorial Board.

Circulation·2026
Same journal

A New <i>Circulation</i>, For You.

Circulation·2026
Same journal

Cardiovascular Risk Reduction With GLP-1 RA Drugs.

Circulation·2026
Same journal

Obesity, Severe Obesity, and Abdominal Obesity in US Youth and Adults From 1999 to 2023.

Circulation·2026
Same journal

Lipid Profile Testing and Interpretation.

Circulation·2026
See all related articles

Related Experiment Video

Updated: May 4, 2026

Improved Generation of Induced Cardiomyocytes Using a Polycistronic Construct Expressing Optimal Ratio of Gata4, Mef2c and Tbx5
10:05

Improved Generation of Induced Cardiomyocytes Using a Polycistronic Construct Expressing Optimal Ratio of Gata4, Mef2c and Tbx5

Published on: November 13, 2015

8.8K

Cellular Reprogramming by PHF7 Enhances Cardiac Function Following Myocardial Infarction.

Glynnis Garry Bann1,2, Matthieu Dos Santos1, Kenian Chen3

  • 1Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX (G.G.B., M.D.S., W.T., S.B., P.C., N.L., R.B.-D., E.N.O.).

Circulation
|July 9, 2025
PubMed
Summary
This summary is machine-generated.

A single epigenetic factor, PHF7, effectively reprograms fibroblasts into cardiomyocytes in mice with heart damage. This discovery offers a promising new strategy for treating ischemic heart disease by enhancing cardiac function and regeneration.

Keywords:
cellular reprogrammingdirect cell reprogramming techniquesepigenomicsheart failuremyocardial infarction

More Related Videos

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

7.4K
Assessing Cardiac Reprogramming using High Content Imaging Analysis
06:02

Assessing Cardiac Reprogramming using High Content Imaging Analysis

Published on: October 26, 2020

1.4K

Related Experiment Videos

Last Updated: May 4, 2026

Improved Generation of Induced Cardiomyocytes Using a Polycistronic Construct Expressing Optimal Ratio of Gata4, Mef2c and Tbx5
10:05

Improved Generation of Induced Cardiomyocytes Using a Polycistronic Construct Expressing Optimal Ratio of Gata4, Mef2c and Tbx5

Published on: November 13, 2015

8.8K
Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

7.4K
Assessing Cardiac Reprogramming using High Content Imaging Analysis
06:02

Assessing Cardiac Reprogramming using High Content Imaging Analysis

Published on: October 26, 2020

1.4K

Area of Science:

  • Cardiovascular Biology
  • Regenerative Medicine
  • Epigenetics

Background:

  • Direct reprogramming of fibroblasts to cardiomyocytes is a promising strategy for ischemic heart disease.
  • Current methods require multiple factors due to fibroblast epigenetic barriers.
  • PHF7 was identified as a potent activator of fibroblast-to-cardiomyocyte reprogramming.

Purpose of the Study:

  • To investigate PHF7's ability to induce reprogramming with minimal factors.
  • To assess the in vivo efficacy of PHF7 in a murine myocardial infarction model.
  • To analyze the functional and molecular impact of PHF7-mediated reprogramming.

Main Methods:

  • In vitro reprogramming assays and genome-wide studies.
  • In vivo myocardial infarction model with retroviral PHF7 delivery.
  • 10X multiomics for transcriptomic and epigenomic analysis in vivo.
  • Genetic fibroblast lineage tracing to confirm reprogramming events.

Main Results:

  • PHF7 addition upregulated unique cardiac transcriptomes and master regulators.
  • In vivo delivery of PHF7 improved cardiac function and remodeling post-infarction.
  • Single-factor PHF7 delivery enhanced survival, function, and reduced fibrosis up to 16 weeks.
  • PHF7 induced bona fide fibroblast-to-cardiomyocyte reprogramming in vivo.
  • Multiomics revealed PHF7's impact on chromatin structure and cellular identity.

Conclusions:

  • A single epigenetic factor, PHF7, can induce reprogramming and improve cardiac function post-myocardial infarction in mice.
  • PHF7 holds potential for treating ischemic heart disease by promoting cardiac repair and regeneration.